Genmab and AbbVie have entered into an oncology partnership to develop and commercialise jointly three of Genmab’s early-stage assets, along with a R&D pact to create four additional cancer drugs. Genmab would receive $750m upfront and $3.15bn in potential milestones and the strengthened financial position would help accelerate R&D activities on other promising assets. Interestingly, Genmab has retained 50% commercialisation rights in the US and Japan, thereby moving a step clos
11 Jun 2020
Genmab and AbbVie to fight cancer together
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Genmab and AbbVie to fight cancer together
Genmab A/S (GMAB:WBO) | 0 0 1.3% | Mkt Cap: 66,508m
- Published:
11 Jun 2020 -
Author:
Sumit Sayal -
Pages:
4
Genmab and AbbVie have entered into an oncology partnership to develop and commercialise jointly three of Genmab’s early-stage assets, along with a R&D pact to create four additional cancer drugs. Genmab would receive $750m upfront and $3.15bn in potential milestones and the strengthened financial position would help accelerate R&D activities on other promising assets. Interestingly, Genmab has retained 50% commercialisation rights in the US and Japan, thereby moving a step clos